Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) and Zeposia (BMS) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis EXTON, Pa., January 29, 2020 /PRNewswire/ —Spherix Global Insights, a […]
Rheumatologists and Nephrologists Anxiously Await New Potential Treatments for Systemic Lupus Erythematosus and Lupus Nephritis, According to Spherix Global Insights
Lupus has high unmet needs and a very active pipeline, including AstraZeneca’s anifrolumab, Eli Lilly’s Olumiant, novel TYK-2 inhibitors from Pfizer and Bristol Myers Squibb, as well as a potential label expansion for GlaxoSmithKline’s Benlysta for renal manifestations EXTON, Pa., September 30, 2020 /PRNewswire/ — Rheumatologists have long struggled to effectively treat patients with systemic […]
Despite Most Specialty Physician Practices Reopening, Engagement with the Pharmaceutical Industry Continues to be Largely Virtual, Placing Added Pressure on Manufacturers Attempting to Introduce New Therapies
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains EXTON, Pa., September 15, 2020 / PRNewswire / – In March, Spherix began tracking the impact of COVID-19 among specialty physicians, specifically dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists. In each wave, approximately 250 specialists share […]
Spherix Global Insights Releases 2021 Publication Plan and Announces New Service, Launch Dynamix™, Fueled by Growing Client Demand
The firm, which was recently recognized by Philadelphia Business Journal as one of the area’s Soaring 76 fastest growing companies for the second year in a row, continues to invest in its areas of deep expertise: dermatology, gastroenterology, nephrology, neurology, and rheumatology EXTON, Pa., August 27, 2020 /PRNewswire/ — Since its founding in 2015, Spherix […]
COVID-19 Continues to Disrupt Patient Care Among Specialty Physicians, Though There Are Early Signs That Recovery is on the Horizon
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing multiple challenges with re-opening EXTON, Pa., July 6, 2020 / PRNewswire / – Results from the seventh wave of an ongoing study examining the impact of COVID-19 on specialty physician practices were released last week […]
Massive Shift in Practice Patterns in Psoriatic Arthritis as Rheumatologists Lean Toward Increased Use of JAK inhibitors and Novel Biologics
Spherix Global Insights releases fifth annual patient chart study focused exclusively on biologic and small molecule switching patterns among US rheumatologists EXTON, Pa., July 2, 2020 /PRNewswire/ – Over the past four years, multiple new agents have been FDA approved for the treatment of psoriatic arthritis (PsA), including Pfizer’s Xeljanz, Eli Lilly’s Taltz, BMS’ Orencia, […]
While Gilead/Galapagos’ Filgotinib Will Have to Contend with the Early Success of AbbVie’s Rinvoq in the US Rheumatoid Arthritis Market, Eli Lilly’s Olumiant is Likely to be the More Formidable Foe in the EU
A stark contrast in use and preference of the JAK inhibitors between the two regions sets varying competitive landscapes for pipeline agents in rheumatoid arthritis EXTON, Pa., July 1, 2020 / PRNewswire / – Analysis of the most recent semiannual report included in Spherix’s RealTime Dynamix™: Rheumatoid Arthritis (EU) service, which captured the responses of […]
EU5 Rheumatologists Expect the Introduction of Janssen’s Tremfya in Psoriatic Arthritis to Blunt Anticipated Growth of Eli Lilly’s Taltz, Novartis’ Cosentyx, and Pfizer’s Xeljanz
A new independent study conducted by Spherix Global Insights reveals projected erosion of branded TNF inhibitors and stabilization of biosimilars and alternate mechanism agents resulting from the introduction of the next likely entrant in the EU5 psoriatic arthritis market EXTON, Pa., June 23, 2020 / PR Newswire / – Spherix recently published the inaugural report […]
Less Than One Year Post Launch, AbbVie’s Rinvoq Disrupts the Rheumatoid Arthritis Treatment Landscape, While a Rich Pipeline Waits in the Wings
The newest market entrant and possibly next autoimmune blockbuster has had an impressive launch so far, according to Spherix Global Insights EXTON, Pa., June 4, 2020 / PR Newswire / –The latest quarterly report included in Spherix’s RealTime Dynamix: Rheumatoid Arthritis (US) service captures the responses of 105 rheumatologists surveyed in May 2020 and highlights […]
Specialty Physicians Report Signs of Rebound from COVID-19, but Are Pessimistic About Reopening Without a Resurgence
According to feedback from the sixth wave of COVID-19 impact tracking, Spherix Global Insights finds that patient volumes remain severely depressed and physicians are worried about patients with non-COVID conditions being able to access care EXTON, Pa., May 27, 2020 / PRNewswire / – Since the end of March, Spherix Global Insights has been tracking […]
